Pharmaceutical & Biotech
BMS to Buy Celgene in Deal Worth $74 Billion, an Industrial Info Market Brief
Bristol-Myers Squibb will acquire Celgene for about $74 billion.
Released Tuesday, January 15, 2019
Pharma-bio giants Bristol-Myers Squibb Company (NYSE:BMY) (BMS) and Celgene Corporation (NASDAQ:CELG) have announced that they have entered into a definitive merger agreement in which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of about $74 billion.
Benefits of the merger range from highly complementary portfolios, with leading franchises in oncology, immunology and inflammation and cardiovascular disease, to about $2.5 billion of expected run-rate cost synergies to be achieved by 2022, according to the companies.
/news/article.jsp
false
Want More IIR News Intelligence?
Make us a Preferred Source on Google to see more of us when you search.
Add Us On GoogleAsk Us
Have a question for our staff?
Submit a question and one of our experts will be happy to assist you.
Forecasts & Analytical Solutions
Where global project and asset data meets advanced analytics for smarter market sizing and forecasting.
Learn More
Industrial Project Opportunity Database and Project Leads
Get access to verified capital and maintenance project leads to power your growth.
Learn MoreIndustry Intel
-
2026 Regional Chemical Processing OutlookOn-Demand Podcast / Mar. 2, 2026
-
From Data to Decisions: How IIR Energy Helps Navigate Market VolatilityOn-Demand Podcast / Nov. 18, 2025
-
Navigating the Hydrogen Horizon: Trends in Blue and Green EnergyOn-Demand Podcast / Nov. 3, 2025
-
ESG Trends & Challenges in Latin AmericaOn-Demand Podcast / Nov. 3, 2025
-
2025 European Transportation & Biofuels Spending OutlookOn-Demand Podcast / Oct. 27, 2025